

WHAT IS THE NIMBLE STUDY?

The study doctors are looking at a possible new medicine for adults and adolescents with eosinophilic asthma (a type of severe asthma). This is called the “study drug”. The doctors want to find out how safe the study drug is and if it works at least as well as the medicines you have already been using to treat your condition (mepolizumab or benralizumab).



WHAT IS THE STUDY DRUG?

In eosinophilic asthma, normal white blood cells called “eosinophils” are increased in number. This may cause inflammation (swelling) of the airways, leading to asthma attacks. It is hoped that the study drug can reduce the number of eosinophils and, therefore, the number of asthma attacks.

The study drug is being developed as an additional therapy for people with eosinophilic asthma who are already taking their usual asthma controller medicines. The study drug has been designed to work in the same way as 2 approved asthma medicines: mepolizumab and benralizumab. You are already receiving either mepolizumab or benralizumab for your asthma. The study drug is given once every 6 months (26 weeks) and it is hoped that this will control your asthma symptoms over a longer period of time. We hope that this will make you feel better and make your asthma care feel less overwhelming.



WHAT ELSE DO I NEED TO THINK ABOUT?

- If you choose to take part in the NIMBLE Study, you may be helping us find ways to help other adults and adolescents with eosinophilic asthma in the future.
- You can choose whether to take part in the NIMBLE Study. You do not have to take part, and you can leave the study at any time.
- The study medication and medical care for the study will be provided at no cost to you.

A team of doctors and nurses will monitor your health carefully during the study.



Try your best to follow all of this advice – please tell the study doctor if you can't and why.